{"id":1015625,"date":"2026-10-30T04:03:35","date_gmt":"2026-10-30T08:03:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/"},"modified":"2026-10-30T04:03:35","modified_gmt":"2026-10-30T08:03:35","slug":"evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/","title":{"rendered":"Evaxion receives International Prix Galien Award for AI-Immunology\u2122 as best digital health solution"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">\n          <b>This international award, honoring \u201cthe best of the best\u201d in medical innovation, represents yet another important external recognition of AI-Immunology\u2122<\/b><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">COPENHAGEN, Denmark, October 30, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology\u2122 platform, is proud to have been awarded the 2026 International Prix Galien Award for AI-Immunology\u2122 as best digital health solution. It is the first time the prestigious international award has been won by a Danish company.<\/p>\n<p align=\"justify\">Evaxion CEO Helen Tayton-Martin and founder and Chief AI Officer Andreas Holm Mattsson received the award last night at the American Museum of Natural History in New York City. It represents yet another important external recognition of AI-Immunology\u2122, which harnesses the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer as well as infectious and autoimmune diseases.<\/p>\n<p align=\"justify\">AI-Immunology\u2122 is Evaxion\u2019s proprietary, clinically validated and scalable AI platform with which it conducts rapid, efficient and high-quality target discovery, drug design and development. Evaxion has discovered and designed several potential new drug candidates with AI-Immunology\u2122, the furthest developed being its personalized cancer vaccine EVX-01. As recently as last week, three-year data from a phase 2 trial with EVX-01, reflecting durable clinical outcomes and immune system activation in advanced melanoma patients was presented at the European Society for Medical Oncology Congress in Madrid.<\/p>\n<p align=\"justify\">\u201cThe International Prix Galien Award is a tremendous recognition of our science and technology, which we are honored and delighted to receive. Having been refined, trained and enhanced for almost two decades, AI-Immunology\u2122 is a leading and clinically validated platform for novel immune drug target discovery, especially in cancer vaccines. We are delighted by this distinction, which strongly endorses our approach in leveraging AI to develop new treatments,\u201d says Helen Tayton-Martin.<\/p>\n<p align=\"justify\">The International Prix Galien Award is presented every two years with eligible nominees having received a national Prix Galien award within the last two years. Thus, it honors \u201cthe best of the best\u201d within different categories of medical innovation. Worldwide, the Prix Galien is often regarded as the equivalent of the Nobel Prize in biopharmaceutical research.<\/p>\n<p align=\"justify\">Evaxion won the Prix Galien UK Award for Best digital health solution in June 2026 and the award for the Best Medical Technology\/AI Advances in the Nordic and high-growth European and Middle Eastern countries in December 2025.<\/p>\n<p align=\"justify\">Founded in France 50 years ago by pharmacist Roland Mehl in honor of Galen, the father of medical science and modern pharmacology, the Prix Galien supports, recognizes and awards the efforts of scientists, researchers and companies committed to advancing medical innovation with the power to change the human condition.<\/p>\n<p align=\"justify\">\n        <b>Contact information<\/b><br \/>\n        <br \/>Evaxion A\/S<br \/>Mads Kronborg<br \/>Vice President, Investor Relations &amp; Communication<br \/>+45 53 54 82 96 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=El2kY7gIZrNLyYY6_V2iQJdba-JJSXbWxUhq4OwQroqzGPest0Yi-sh1KOkPM9U6SXb6GwTuWRqvFsFJz4Ajaw==\" rel=\"nofollow\" target=\"_blank\">mak@evaxion.ai<\/a><\/p>\n<p align=\"justify\">\n        <b>About Evaxion<\/b><br \/>\n        <br \/>Evaxion is a pioneering clinical-stage TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology\u2122. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer as well as infectious and autoimmune diseases.<\/p>\n<p align=\"justify\">With AI-Immunology\u2122 we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.<\/p>\n<p align=\"justify\">We have developed a pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients\u2019 lives by providing innovative and targeted treatment options.<\/p>\n<p align=\"justify\">For more information about Evaxion, AI-Immunology\u2122 and our pipeline, please visit our <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SRD4fPMCGKeDcoJzEwJ--oT1eXpD-Adb30ysBNfY5OiXKOjYdMDcyo9yrhj5_Aq_8IxEy6uOVPT1sQ4raHSt0w==\" rel=\"nofollow\" target=\"_blank\">website<\/a>.\u00a0<\/p>\n<p align=\"justify\">\n        <b>Forward-looking statement<\/b>\u00a0<br \/>This\u00a0announcement contains forward-looking statements\u00a0within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.\u00a0The words\u00a0\u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201chope,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201canticipate,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d and other words and terms of similar meaning\u00a0identify forward-looking statements.\u00a0Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares,\u00a0the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our\u00a0business from other significant geopolitical and macro-economic events;\u00a0and other uncertainties affecting our business operations and financial condition.\u00a0For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F\u00a0and other filings\u00a0with the US Securities and Exchange Commission (SEC), which are available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=olekFYWOqJC1amG2U8EUEeuG_dFSfYsN1wCeZlXJm4RE6Mx9P358izsp6A1Cc_MmrQ9JdEygMCnSu5Tj4b6_SqTKud7wnD4H8RRvfDzlHmwLkB7qGx1-4cfXbC5s3BonKmLDHJP3CR5_SMDZoh8olVV__Ef3p1Pur-bg_hRIbFtOxAkBvDUDiI-yTKgWLciDjCS22_LYhBAHIUzwtqOvvzPPAhls028mkwbcwQnp_TY=\" rel=\"nofollow\" target=\"_blank\"><b>www.sec.gov<\/b><\/a>.\u00a0We do not assume any obligation to update any forward-looking statements except as required by law.\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI4MDgwNSM0MDI1MzU4MDQjMjI1MjA4Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/ZmJiOWIwMTYtYjFlOS00MWFlLThkNzItYzE1M2E5ZDhkNTJhLTEyNjM2NDAtMjAyNi0xMC0zMC1lbg==\/tiny\/Evaxion.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>This international award, honoring \u201cthe best of the best\u201d in medical innovation, represents yet another important external recognition of AI-Immunology\u2122 COPENHAGEN, Denmark, October 30, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology\u2122 platform, is proud to have been awarded the 2026 International Prix Galien Award for AI-Immunology\u2122 as best digital health solution. It is the first time the prestigious international award has been won by a Danish company. Evaxion CEO Helen Tayton-Martin and founder and Chief AI Officer Andreas Holm Mattsson received the award last night at the American Museum of Natural History in New York City. It represents yet another important external recognition of AI-Immunology\u2122, which harnesses the power &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Evaxion receives International Prix Galien Award for AI-Immunology\u2122 as best digital health solution&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1015625","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Evaxion receives International Prix Galien Award for AI-Immunology\u2122 as best digital health solution - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaxion receives International Prix Galien Award for AI-Immunology\u2122 as best digital health solution - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"This international award, honoring \u201cthe best of the best\u201d in medical innovation, represents yet another important external recognition of AI-Immunology\u2122 COPENHAGEN, Denmark, October 30, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology\u2122 platform, is proud to have been awarded the 2026 International Prix Galien Award for AI-Immunology\u2122 as best digital health solution. It is the first time the prestigious international award has been won by a Danish company. Evaxion CEO Helen Tayton-Martin and founder and Chief AI Officer Andreas Holm Mattsson received the award last night at the American Museum of Natural History in New York City. It represents yet another important external recognition of AI-Immunology\u2122, which harnesses the power &hellip; Continue reading &quot;Evaxion receives International Prix Galien Award for AI-Immunology\u2122 as best digital health solution&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-30T08:03:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI4MDgwNSM0MDI1MzU4MDQjMjI1MjA4Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Evaxion receives International Prix Galien Award for AI-Immunology\u2122 as best digital health solution\",\"datePublished\":\"2026-10-30T08:03:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\\\/\"},\"wordCount\":866,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI4MDgwNSM0MDI1MzU4MDQjMjI1MjA4Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\\\/\",\"name\":\"Evaxion receives International Prix Galien Award for AI-Immunology\u2122 as best digital health solution - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI4MDgwNSM0MDI1MzU4MDQjMjI1MjA4Nw==\",\"datePublished\":\"2026-10-30T08:03:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI4MDgwNSM0MDI1MzU4MDQjMjI1MjA4Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI4MDgwNSM0MDI1MzU4MDQjMjI1MjA4Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evaxion receives International Prix Galien Award for AI-Immunology\u2122 as best digital health solution\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaxion receives International Prix Galien Award for AI-Immunology\u2122 as best digital health solution - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/","og_locale":"en_US","og_type":"article","og_title":"Evaxion receives International Prix Galien Award for AI-Immunology\u2122 as best digital health solution - Market Newsdesk","og_description":"This international award, honoring \u201cthe best of the best\u201d in medical innovation, represents yet another important external recognition of AI-Immunology\u2122 COPENHAGEN, Denmark, October 30, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology\u2122 platform, is proud to have been awarded the 2026 International Prix Galien Award for AI-Immunology\u2122 as best digital health solution. It is the first time the prestigious international award has been won by a Danish company. Evaxion CEO Helen Tayton-Martin and founder and Chief AI Officer Andreas Holm Mattsson received the award last night at the American Museum of Natural History in New York City. It represents yet another important external recognition of AI-Immunology\u2122, which harnesses the power &hellip; Continue reading \"Evaxion receives International Prix Galien Award for AI-Immunology\u2122 as best digital health solution\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-30T08:03:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI4MDgwNSM0MDI1MzU4MDQjMjI1MjA4Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Evaxion receives International Prix Galien Award for AI-Immunology\u2122 as best digital health solution","datePublished":"2026-10-30T08:03:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/"},"wordCount":866,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI4MDgwNSM0MDI1MzU4MDQjMjI1MjA4Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/","name":"Evaxion receives International Prix Galien Award for AI-Immunology\u2122 as best digital health solution - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI4MDgwNSM0MDI1MzU4MDQjMjI1MjA4Nw==","datePublished":"2026-10-30T08:03:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI4MDgwNSM0MDI1MzU4MDQjMjI1MjA4Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI4MDgwNSM0MDI1MzU4MDQjMjI1MjA4Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Evaxion receives International Prix Galien Award for AI-Immunology\u2122 as best digital health solution"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1015625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1015625"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1015625\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1015625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1015625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1015625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}